Match!
Isao Kamae
University of Tokyo
Health careIntensive care medicinePhysical therapyPopulationMedicine
92Publications
16H-index
1,252Citations
What is this?
Publications 96
Newest
#1Gordon G. Liu (PKU: Peking University)H-Index: 19
#2Eric Q. Wu (AG: Analysis Group)H-Index: 42
Last. Hongbo Yang (AG: Analysis Group)H-Index: 11
view all 6 authors...
Abstract Health technology assessment (HTA) has long been employed by many countries around the world, but its adoption in Asia has been slower. Only recently have a growing number of Asian countries started to implement HTA for pricing and reimbursement decisions. The objective of this article is to provide an overview of how HTA has been or is being implemented in Asia within the context of a country’s existing—and often complex—coverage, reimbursement, and pricing schemes. Three countries at ...
Source
#1Toshifumi Hibi (Kitasato University)H-Index: 72
#2Isao Kamae (UTokyo: University of Tokyo)H-Index: 16
Last. Haridarshan Patel (Takeda Pharmaceutical Company)H-Index: 4
view all 7 authors...
Background/Aims: Several biologic therapies are approved in Japan to treat moderately to severely active ulcerative colitis (UC), but there are no published comparative efficacy studies in a Japanese population. We compared the efficacy of biologics approved in Japan (adalimumab, infliximab, golimumab, and vedolizumab) for treating biologic-naive patients with UC at their approved doses. Methods: A targeted literature review identified 4 randomized controlled trials of biologics for UC in biolog...
Source
#1Isao Kamae (UTokyo: University of Tokyo)H-Index: 16
#2R Thwaites (Takeda Pharmaceutical Company)H-Index: 2
Last. Jovelle Fernandez (Takeda Pharmaceutical Company)
view all 4 authors...
AbstractBackground: In Japan, pharmacoeconomic requirements for list-price adjustment were institutionalized in April 2019 following provisional implementation of a new Health Technology Assessment...
Source
#1Suerie Moon (HEI: Graduate Institute of International and Development Studies)H-Index: 19
#2Stephanie Mariat (WHO: World Health Organization)H-Index: 1
Last. Hanne Bak PedersenH-Index: 10
view all 4 authors...
3 CitationsSource
#1Isao Kamae (UTokyo: University of Tokyo)H-Index: 16
Source
#1Isao Kamae (UTokyo: University of Tokyo)H-Index: 16
Pharmacoeconomic (PE) evaluation has evolved rapidly in recent years in Europe and the USA as a method of analysis to assist with decisionmaking for the funding and management of pharmaceuticals and, more broadly, medical devices and services, in order to address issues related to national healthcare systems and health insurance programs. PE guidelines provide guidelines for that process and can be used as a standard format for decisionmaking by the government, as a guide for designing and condu...
Source
#1Isao Kamae (UTokyo: University of Tokyo)H-Index: 16
The process for cost-effectiveness evaluation of Chuikyo consists of the following four steps: (1) submission of data by companies, (2) reanalysis, (3) appraisal, and (4) decision-making based on the results. Steps 1 and 2 refer to “assessment,” which is followed by the appraisal. The approach to conducting an appraisal is outlined in Chuikyo’s handout discussed in Chap. 3, which can be summarized as follows:
Source
#1Isao Kamae (UTokyo: University of Tokyo)H-Index: 16
The monthly cost of pharmaceutical treatment for nine patients with disease X was found to be JPY 150, 190, 220, 260, 210, 100, 130, 120, and 150K, respectively.
Source
#1Isao Kamae (UTokyo: University of Tokyo)H-Index: 16
Generally, the relationship between cost and effectiveness is not proportional: While effectiveness increases with increase in cost, the growth rate gradually diminishes. This relationship is known in economics as the law of diminishing marginal utility. In a two-dimensional graph, if we represent effectiveness on the horizontal axis and cost on the vertical axis as in Fig. 7.1, the cost-effectiveness function is expressed as convex and downward, monotonically increasing from the lower left hand...
Source
#1Isao Kamae (UTokyo: University of Tokyo)H-Index: 16
When performing a decision analysis that involves diagnostic testing, the approach used to illustrate the test in a decision tree and to assign probabilities requires special attention. To better understand this, we first need to understand the characteristics of a diagnostic test. A diagnostic test has the following four characteristics that measure its performance in identifying the condition of interest: (1) sensitivity (or the true-positive rate, i.e., the probability of a positive test give...
Source
12345678910